Hypertension afflicts the largest population in the United States. Even though we now have effective and high quality life, medical therapeutic modalities, many patients are diagnosed after the onset of irreversible morbid sequelae of hypertension (stroke, congestive heart failure, atherosclerosis, irreversible renal failure). Moreover, we still do not understand fundamental mechanisms of essential hypertension of genetic or environmental etiology. The objective of this program is to train both basic and clinical biomedical scientists in cardiovascular research, particularly in areas related to hypertension, at both pre- and post-doctoral levels, who show long term commitment for research. The multi-disciplinary collaborative approach has been a long standing policy of our training program. This system is particularly germane at this juncture with the specific purpose of training researchers well versed in the principles and techniques of modern and rapidly changing environment of research directed toward molecular and cell biology and genetics. The multi- factorial nature of hypertensive disease and its consequence in diverse manifestation of degenerative organ damage logically demands such a multi-faceted approach. This program consists of 23 investigators representing areas of research relevant to hypertension, blood pressure regulation and related cardiovascular and renal diseases, which includes molecular genetics, molecular biology of signal transduction, and central and neuronal mechanisms, 4 from Pharmacology, 3 from Biochemistry, 1 from Pathology, 4 from the Division of Nephrology, 3 from Cardiology and 6 from Clinical Pharmacology. Four pre-doctoral trainees will be selected from 50 (55 for 1999) interdepartmental Graduate Program students (IGP) who have been supported by University funds during their first nine months. Four post-doctoral trainees are proposed. In addition to continuing vigorous recruitment of minority trainees through personal contacts and advertisement, participation of a faculty member of Meharry Medical College supported by Minority Institution Mentored Faculty Research Award allows our access to minority students.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
2T32HL007323-21
Application #
2799797
Study Section
Special Emphasis Panel (ZHL1-CSR-K (F1))
Project Start
1979-07-01
Project End
2004-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
21
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Biochemistry
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Ohtsu, Haruhiko; Frank, Gerald D; Utsunomiya, Hirotoshi et al. (2005) Redox-dependent protein kinase regulation by angiotensin II: mechanistic insights and its pathophysiology. Antioxid Redox Signal 7:1315-26
Osler, Megan E; Bader, David M (2004) Bves expression during avian embryogenesis. Dev Dyn 229:658-67
Apparsundaram, S; Sung, U; Price, R D et al. (2001) Trafficking-dependent and -independent pathways of neurotransmitter transporter regulation differentially involving p38 mitogen-activated protein kinase revealed in studies of insulin modulation of norepinephrine transport in SK-N-SH cells. J Pharmacol Exp Ther 299:666-77
Apparsundaram, S; Ferguson, S M; George Jr, A L et al. (2000) Molecular cloning of a human, hemicholinium-3-sensitive choline transporter. Biochem Biophys Res Commun 276:862-7
Zaucha, J A; Westphal, R S; Wadzinski, B E (1998) protein phosphatase 2A regulatory subunits. cDNA cloning and analysis of mRNA expression. Methods Mol Biol 93:279-91
Takahasi, K; Bardhan, S; Kambayashi, Y et al. (1994) Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor, AT2. Biochem Biophys Res Commun 198:60-6
Inagami, T; Iwai, N; Sasaki, K et al. (1993) Angiotensin II receptors: cloning and regulation. Arzneimittelforschung 43:226-8
Abels, B C; Branch, R A; Sabra, R (1993) Interaction between thromboxane A2 and angiotensin II in postischemic renal vasoconstriction in dogs. J Pharmacol Exp Ther 264:1285-92
Brown, N J; Ryder, D; Nadeau, J (1993) Caffeine attenuates the renal vascular response to angiotensin II infusion. Hypertension 22:847-52
Kambayashi, Y; Bardhan, S; Takahashi, K et al. (1993) Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268:24543-6

Showing the most recent 10 out of 19 publications